ICYMI: The SEC is litigating what some observers are a calling a first-of-its-kind insider trading case against a pharma executive who allegedly bought stock in a rival company after hearing that his own company was about to be acquired.
http://dlvr.it/SLlbPn
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.